Sarcomas

Brian Van Tine, MD, PhD, discusses the potential of the investigational compound 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and nonresectable soft tissue sarcoma.

Marcus Albertsmeier, MD, surgeon at Ludwig Maximilian University of Munich, discusses the effect of radiation therapy on local recurrence and overall survival for patients with soft tissue sarcoma.

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses a phase II trial exploring concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Nancy B. Gordon, MD, assistant professor, department of pediatrics, The University of Texas MD Anderson Center, discusses immunotherapy treatments for osteosarcoma.

Markus Albertsmeier, MD, discusses the results of the meta-analysis and the implications going forward for the treatment of patients with soft tissue sarcoma.

Jean-Yves Blay, MD, PhD, professor of Medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the heterogeneity of soft tissue sarcoma.

An immunohistochemistry analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam.

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses some of the data seen thus far with trabectedin as a treatment for patients with sarcoma.

Seth M. Pollack, MD, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the potential impact that radiomics could have on the treatment landscape of sarcoma.

Charles Catton, MD, professor, Department of Radiation Oncology, University of Toronto, discusses the notion of omitting radiation therapy in the treatment of patients with extremity sarcoma.

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses results of a phase II study exploring the efficacy of imatinib (Gleevac) in patients with racist progressive demoed tumors.

In the phase II SARC028 trial, single-agent pembrolizumab (Keytruda) demonstrated antitumor activity in patients with advanced soft tissue and bone sarcomas.

Researchers are hoping the immunotherapy revolution occurring across several cancer types will extend to the field of sarcoma.

According to Dimosthenis Andreou, MD, patients with pelvic Ewing sarcoma have poorer local control and poorer overall survival.

Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with olaratumab (Lynparza) in pediatric sarcoma models.

According to Nancy Gordon, MD, immunotherapy stands to play a critical role in the treatment of patients with osteosarcoma and lung metastases.

Excitement continues to surround the potential role of immunotherapy agents in the treatment of patients with sarcoma, according to Breelyn Wilky, MD.

Several challenges remain in the treatment landscape of soft tissue sarcoma, a disease whose diagnosis can range from one that is quite indolent for patients, to a more life-threatening, metastatic, aggressive cancer.

The combination of TRC105, an endoglin antibody, and pazopanib demonstrated promising antitumor activity in patients with advanced angiosarcoma

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the role of radiomics in the treatment landscape of sarcoma.

Dimosthenis Andreou, MD, orthopedic oncologist, University Hospital Münster, discusses prognosis factors in patients with Ewing sarcoma.

Pembrolizumab reduced the size of tumors in patients with a subtype of soft tissue sarcoma, according to updated interim results from the phase II SARC028, multicenter clinical trial, which were reported at the most recent meeting of the Connective Tissue Oncology Society in Lisbon, Portugal.

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.

The European Commission has granted an accelerated approval to olaratumab in combination with doxorubicin as a frontline therapy for patients with advanced soft tissue sarcoma, making it the first new therapy for this indication in over 40 years.

Markus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses a a meta-analysis of the effect of radiation therapy on local recurrence and overall survival in patients with soft tissue sarcoma.